Evidence map›Paper›PMID 38596427›Full record

ArticleThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG2024

Ceftriaxone Pharmacokinetics and Pharmacodynamic Target Attainment for Three Pediatric Patients Receiving Continuous Kidney Replacement Therapy.

H Rhodes Hambrick, Francisco Cervantes, Min Dong, Peter Tang, Trent Arbough, Alexander A Vinks, Tomoyuki Mizuno, Stuart L Goldstein, Jennifer Kaplan, Sonya Tang Girdwood

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

H Rhodes HambrickDivision of Nephrology and Hypertension (HRH, SLG), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Francisco CervantesDepartment of Medical Education (FC), University of Cincinnati College of Medicine, Cincinnati, OH.
Min DongDivision of Clinical Pharmacology (HRH, MD, AAV, TM, STG), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Peter TangDepartment of Pediatrics (MD, PT, AAV, TM, SLG, JK, STG), University of Cincinnati College of Medicine, Cincinnati, OH.
Trent ArboughDepartment of Anesthesiology (TA), University of Kentucky College of Medicine, Lexington, KY.
Alexander A VinksDivision of Clinical Pharmacology (HRH, MD, AAV, TM, STG), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Tomoyuki MizunoDivision of Clinical Pharmacology (HRH, MD, AAV, TM, STG), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Stuart L GoldsteinDivision of Nephrology and Hypertension (HRH, SLG), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Jennifer KaplanDepartment of Pediatrics (MD, PT, AAV, TM, SLG, JK, STG), University of Cincinnati College of Medicine, Cincinnati, OH.
Sonya Tang GirdwoodDepartment of Pediatrics (MD, PT, AAV, TM, SLG, JK, STG), University of Cincinnati College of Medicine, Cincinnati, OH.
Cincinnati Children's Hospital Medical Center · USUniversity of Cincinnati Medical Center · USUniversity of Kentucky · US

Funding

T32 Cincinnati Pediatric Clinical Pharmacology Training ProgramT32HD069054 · NICHD · CINCINNATI CHILDRENS HOSP MED CTR · PI TRACY A GLAUSER, Sonya C Tang Girdwood · 2011 to 2026
$3.0M
RESEARCH TRAINING IN PEDIATRIC NEPHROLOGYT32DK007695 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI DEVARAJAN, PRASAD · 1992 to 2023
$2.2M
Antibiotic Model-Informed Precision Dosing in Critical IllnessR35GM146701 · NIGMS · CINCINNATI CHILDRENS HOSP MED CTR · PI Sonya C Tang Girdwood · 2022 to 2026
$2.0M
Model-Informed Evaluation of Hydroxyurea Exposure in Special PopulationsK01MD017289 · NIMHD · CINCINNATI CHILDRENS HOSP MED CTR · PI DONG, MIN · 2022 to 2023
$179k
NICHD NIH HHS T32 HD069054NIDDK NIH HHS T32 DK007695NIGMS NIH HHS R35 GM146701NIMHD NIH HHS K01 MD017289
6 · The paper itself

Abstract

Ceftriaxone is used commonly for sepsis, including in children requiring continuous kidney replacement therapy (CKRT). No reports exist of pharmacokinetic (PK) parameters for children receiving ceftriaxone on CKRT. We enrolled children admitted to our pediatric intensive care unit (PICU) who received CKRT for >24 hours and received >1 dose of ceftriaxone while on and off CKRT. We measured free ceftriaxone -concentrations from residual blood samples then used Bayesian estimation with PK modeling software to generate concentration-time profiles and determine PK parameters and the percentage of time free ceftriaxone concentrations were above 1× or 4× MIC (%

Indexed as

acute kidney injuryceftriaxonecontinuous renal replacement therapyextracorporeal clearance

Identifiers

PMID38596427
PMCPMC11001209
OpenAlexW4394581098

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.